Poteligeo is approved for usage in mycosis fungoides patients who have received two systemic therapies earlier. Credit: Martin Trotter / Flickr.

The UK National Institute for Health and Care Excellence (Nice) has recommended Kyowa Kirin’s humanised monoclonal antibody, Poteligeo (mogamulizumab), to treat adult patients with ultra-rare blood cancers in England and Wales.

The positive guidance published by NICE noted that the drug is indicated for the treatment of two cutaneous T-cell lymphoma (CTCL) types, mycosis fungoides (MF) and Sézary syndrome (SS).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mogamulizumab targets and binds to the CC chemokine receptor 4 (CCR4), thereby boosting immune cells to kill cancerous cells.

CCR4 is a protein expressed on cancerous cells observed in MF and SS.

Poteligeo is approved for usage in MF patients who have already received two systemic therapies and for individuals suffering from SS and who received one systemic treatment earlier.

In March, NICE had decided not to recommend Poteligeo for routine usage in the UK National Health Service (NHS) citing uncertain clinical data.

The guidance was published in the form of a Final Appraisal Determination that comes after the company and various parties including Lymphoma Action, Leukaemia Care and the UK Cutaneous Lymphoma Group (UKCLG) appealed for the use of Poteligeo to treat MF and SS.

Kyowa Kirin Northern Cluster general manager responsible for the UK Richard Johnson said: “By issuing positive guidance for Poteligeo, NICE has helped ensure that those with MF and SS who have few systemic treatment options available to them are now able to access an innovative therapy.

“This decision is also a testament to the dedication, commitment and long-term efforts of the broader CTCL community in advocating for a wider range of treatment options in the UK for those living with conditions like MF and SS.”

NICE had recommended Bristol Myers Squibb’s nivolumab (Opdivo) for the treatment of oesophageal cancer last month.